Effect of homocysteine-lowering therapy on vascular endothelial function and exercise performance in coronary patients with hyperhomocysteinaemia

Acta Cardiologica

Volumn 58, Issue 5, 2003, Pages 389-396

  Dinckal, Mustafa Hakan ^a,d   Aksoy, Nur ^b   Aksoy, Mehmet ^a   Davutoglu, Vedat ^a   Soydinc, Serdar ^a   Kirilmaz, Ata ^c   Dinckal, Nurten ^b   Akdemir, Ilyas ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Gaziantep State Hospital   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d NONE   (Turkey)

Author keywords

Endothelial function; Homocysteine; Myocardial ischaemia; Treadmill exercise test

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYANOCOBALAMIN; FOLIC ACID; GLYCERYL TRINITRATE; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; ECHOGRAPHY; EXERCISE; EXERCISE TEST; HUMAN; HYPERCHOLESTEROLEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PATHOPHYSIOLOGY; PERFORMANCE; PROSPECTIVE STUDY; ST SEGMENT DEPRESSION; TREADMILL ERGOMETRY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ANALYSIS OF VARIANCE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; EXERCISE TEST; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASODILATION; VITAMIN B 12; VITAMIN B 6;

EID: 0142058238     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.58.5.2005302     Document Type: Article

References (38)

1. Haller H. Risk factors for cardiovascular disease and the endothelium. Born GVR, Schwartz CJ (eds). Vascular endothelium: Physiology, pathology and therapeutic opportunities. Schattauer, Stuttgart, 1997: 273-4.
2. Vanhoutte PM. The endothelium. Modulator of vascular smooth muscle tone. N Engl J Med 1988; 319: 512-3.
3. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988; 93: 515-24.
4. Iiyama K, Nagano M, Yo Y, Nagano N, Kamide K, Higaki J, Mikami H, Ogihara T. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996; 132: 779-82.
5. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23: 833-43.
6. Celermajer DS, Sorensen K, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149-55.
7. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
8. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-21.
9. Celermayer DS, Sorensen K, Ryalls M, Leonard J, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-8.
10. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
11. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IM, Noble MIM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000; 102: 605-10.
12. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD Jr, Winters WL, Yanowitz FG, Ritchie JL, Gibbons RJ, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA Guidelines for exercise testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1997; 30: 260-311.
13. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G et al. For the European Concerted Action Project: plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-8.
14. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
15. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
16. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest J. Homocysteine and coronary artery disease in French-Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate and folate. Am J Cardiol 1995; 75: 1107-11.
17. 6 concentrations: risk factors for stroke, peripheral vascular disease and coronary artery disease. Circulation 1998; 97: 437-43.
18. Stampfer MJ, Malinow MR, Willet WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
19. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-18.
20. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24-9.
21. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-4.
22. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 1998; 351: 36-7.
23. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for health care professional from the nutrition comittee, American Heart Association. Circulation 1999; 99: 178-82.
24. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
25. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93.
26. Clarkson P, Aarsen M, Donker AJM. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28: 573-9.
27. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
28. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998; 31: 552-7.
29. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
30. Gotto AM Jr. Lipid lowering, regression and coronary events: a rewiev of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, seventh council meeting. Circulation 1995; 92: 646-56.
31. rd. Contribution of nitric oxide to metabolic coronary vasodilation in human heart. Circulation 1995; 92: 320-6.
32. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patient with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986; 73: 865-76.
33. Gordon JB, Ganz P, Nabel EG, Fish RD, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989; 83: 1946-52.
34. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990; 81: 850-9.
35. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic arteries induced by increases in heart rate. Circulation 1990; 81: 850-9.
36. Mansur AP, Serrano CV Jr, Nicolau JC, César LAM, Ramires JAF. Effect of cholesterol lowering treatment on positive exercise tests in patient with hypercholesterolemia and normal coronary angiograms. Heart 1999; 82: 689-93.
37. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8.
38. 6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355: 517-22.